Poolbeg Pharma (LON:POLB) Sets New 12-Month High – Should You Buy?

Poolbeg Pharma PLC (LON:POLB)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 9.30 and last traded at GBX 9.30, with a volume of 2141301 shares trading hands. The stock had previously closed at GBX 8.95.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a research note on Monday, July 13th.

Poolbeg Pharma Stock Performance

The company’s 50 day simple moving average is GBX 7.78 and its 200 day simple moving average is GBX 6.24. The stock has a market cap of £66.42 million, a PE ratio of -9.26 and a beta of 1.83.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.